Next Article in Journal
Understanding the Role of Cancer Diagnosis in the Associations between Personality and Life Satisfaction
Previous Article in Journal
Perceived Cardiovascular Disease Risk Following Preeclampsia: A Cross-Sectional Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Healthcare
Volume 11
Issue 16
10.3390/healthcare11162358
healthcare-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Dose-Response Relationship between Gestational Weight Gain and Neonatal Birthweight in Chinese Women with Excess Weight/Obesity and Gestational Diabetes Mellitus

by
Jing He
1,2,
Kaili Hu
1,
Binghua Wang
1,
Zhen Chen
3 and
Hui Wang
1,*
1
Nursing Department, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan 430030, China
2
School of Nursing, Tongji Medical College of Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China
3
Department of Gynaecology and Obstetrics, Chongqing Health Center for Women and Children (Women and Children’s Hospital of Chongqing Medical University), 120 Longshan Road, Chongqing 401147, China
*
Author to whom correspondence should be addressed.
Healthcare 2023, 11(16), 2358; https://doi.org/10.3390/healthcare11162358
Submission received: 23 June 2023 / Revised: 10 August 2023 / Accepted: 13 August 2023 / Published: 21 August 2023
(This article belongs to the Section Women's Health Care)
Browse Figures
Review Reports Versions Notes

Abstract

:
Total gestational weight gain (GWG) is identified as a strong and potentially controllable predictor of long-term health outcomes in women with gestational diabetes mellitus (GDM) and infants. When the total GWG of women with excess weight/obesity and GDM does not exceed the Institute of Medicine (IOM) suggested range, neonatal birthweight outcomes may be favorable, but the evidence is limited. Therefore, the objective of this study was to evaluate the dose-response relationship between increased total GWG and the risk of neonatal birthweight in Chinese women with excess weight/obesity and GDM. This study obtained electronic medical records (EMR) from the hospital information system (HIS) of the Chongqing Health Center for Women and Children between July 2017, and June 2020. A retrospective study analyzed the effect of the total GWG of women with excess weight/obesity and GDM on neonatal birthweight. The dose-response relationship between total GWG and neonatal birthweight was studied using a generalized linear model and embedded restricted cubic splines (RCS). The average age of all women with GDM was 31.99 ± 4.47 years, and 27.61% were advanced maternal age (≥35 years). The total GWG among women with excess weight and obesity and GDM greater than the IOM recommendations were found in 42.96% and 58.62% of cases, respectively. Total GWG in women with excess weight and excessing the IOM recommended range is a risk factor for large gestational age (LGA) [adjusted odds ratio (aOR) 0.1.47, 1.08–2.01] and macrosomia (aOR 1.55, 1.04–2.31). In the obesity above group, excessive weight gain increased the risk of LGA (aOR 2.92, 1.33–6.41) and macrosomia (aOR 2.83, 1.03–7.72). We used an RCS to examine pregnant women with excess weight and GDM and discovered a linear dose-response relationship between total GWG and LGA/macrosomia. In women with excess weight and obesity, increases in total GWG above the lowest end of the IOM recommendations range (7 kg and 5 kg) were associated with an increased risk of LGA and macrosomia. Therefore, research is urgently needed to support maternal and newborn health to provide recommendations for the ideal weight increase in women with excess weight/obesity and GDM.

1. Introduction

Weight gain and obesity are serious global health problems and independent primary risk factors for gestational diabetes mellitus (GDM) [1]. Women with pre-pregnancy excess weight or obesity may experience increased insulin resistance during pregnancy and exacerbate hyperglycemia, which can be further aggravated by excessive weight gain [2,3]. GDM is primarily diagnosed in the second and third trimesters of pregnancy and is defined as any level of glucose intolerance initially detected during pregnancy [4]. Traditional approaches to GDM management have centered on monitoring and treating it throughout pregnancy to control hyperglycemia in pregnant women. Studies suggest adequate glycemic control in pregnant women can prevent poor outcomes for mothers and neonates [5,6,7]. However, some studies have found that women with excess weight/obesity and blood glucose levels in the normal range have higher large gestational age (LGA) outcomes than women with average or low pre-pregnancy weight [8,9]. Furthermore, excess weight/obesity and GDM may exacerbate adverse neonatal effects, especially the LGA and macrosomia [10,11].
Many factors influence GDM and unfavorable pregnancy outcomes, including pre-pregnancy excess weight/obesity, proper glycemic control, treatment modalities (diet and physical exercise alone or in combination with medication), changes in the gut microbiota, and gestational weight increase [3,12]. Komen et al. found that total weight change was associated with poor blood glucose control, cesarean section, and excessive amniotic fluid [13]. According to Hedderson et al., substantial weight gain may increase the risk of poor glycemic control during pregnancy and postpartum in women with GDM [14]. The Institute of Medicine (IOM) suggested updated guidelines for GWG (gestational weight gain) in 2009. Still, they did not address GWG in high-risk pregnancies or whether more stringent requirements for weight gain could reduce the adverse effects of hyperglycemia [15]. The synergistic effect of excessive weight gain and blood glucose control is essential for enhancing adverse pregnancy outcomes with GDM.
Goldstein et al. discovered that GWG was significantly higher than the IOM recommendations for body weight increase in 47% of pregnancies in a meta-analysis involving approximately 130,000 pregnant women studying GWG and pregnancy outcomes [11]. The IOM has published guidance for appropriate weight gain during pregnancy for healthy pregnant women in each preconception body mass index (BMI) category [15]. And the recommendations are based on the weight gained during pregnancy to achieve the ideal neonatal birthweight [15]. Studies discovered, however, that women with GDM and pre-pregnancy obesity were more likely to exceed the IOM’s suggested criteria [16,17]. Furthermore, studies have revealed that the total GWG of women with GDM is below the IOM recommendations value can reduce adverse pregnancy outcomes, and are favorable to postpartum metabolism [18,19].
GWG has been identified as a strong and potentially controllable predictor of short-and long-term health outcomes in women and infants with GDM, increasing the risk of LGA and macrosomia [18,19]. Mustaniemi et al. reported that GDM, obesity, and excess GWG are associated with a higher risk of LGA in infants, and interventions targeting normal GWG are also likely to reduce LGA rates and birthweight standard deviation scores [20]. However, another study in the Chinese population found that GWG was advantageous for neonatal birthweight outcomes in obese women with GDM below the range suggested of IOM criteria [21]. Additionally, there is a pathophysiological mechanism by which insulin resistance is also impacted by obesity and high total GWG. More glucose crosses the placenta and reaches the fetus due to increased maternal insulin resistance, leading to macrosomia or LGA [21].
In recent years, there has been an upsurge in fetal overgrowth, which may offer a significant risk for future juvenile obesity and diabetes. Fetuses of women with GDM are more likely to have LGA/macrosomia [22]. The current study provides little data on ideal gestational total weight increase in overweight/obese women with GDM and its impact on neonatal birthweight. There is an urgent need to give women with excess weight/obesity and GDM proper weight counseling to decrease total GWG and keep neonatal weight within the normal range. Furthermore, there is a lack of research on the association between sequential changes in weight increase in overweight/obese and GDM women and neonatal weight. To ascertain the impact of total GWG on neonatal outcomes for women with excess weight/obesity and GDM, both below and above IOM recommendations, was the primary objective of this study. Further research was done on the dose-response association between total GWG and the probability of having a low newborn weight.

2. Materials and Methods

The Chinese Clinical Trial Registry (ChiCTR) registered this study under registration number ChiCTR2000040588 on 3 December 2020. Furthermore, this study was conducted following the statement of the Report on Enhanced Observational Studies in Epidemiology (STROBE) [23].

2.1. Procedures and Participants

The retrospective study was conducted by Obstetric Department of the Chongqing Health Center for Women and Children Between 1 July 2017, and 30 June 2020. And we acquired clinical data (electronic medical records) about women with excess weight/obesity, GDM, and neonates. This study included pregnant women older than 18 years old, had pre-pregnancy BMI that were overweight or obese, were diagnosed with GDM during pregnancy, and reported single and live birth outcomes for the mother and the newborn. The present study excluded pregnant women with type 1 and type 2 diabetes mellitus (T2DM) diagnosed before pregnancy, the absence of core information on total gestational weight gain (GWG), and hereditary diseases of neonates. Furthermore, the presence of infectious diseases in the mother was excluded. This study reviewed three years of clinical data from a single center.

2.2. Data Collection Procedures

We obtained clinical parameters and laboratory test results from the hospital information system (HIS) of pregnant women diagnosed with GDM and their paired newborns. We entered them into a standardized template database. We collected data from medical records using the double-entry method to ensure data accuracy. All patient information is anonymized and numbered instead, with no direct patient participation. The data collected included: maternal information (maternal age, pre-pregnancy BMI, gestational number, gestational number and family history of T2DM), maternal, perinatal outcomes (results of three OGTT tests, insulin use, preeclampsia, and delivery mode), and neonatal-perinatal outcomes (gestational age, neonatal gender, weight, hypoglycemia, and hyperbilirubinemia).

2.3. Diagnosis and Definitions

Gestational diabetes mellitus was diagnosed based on Chinese guidelines for diagnosis and treatment of GDM with a slightly higher fasting threshold (75 g oral glucose tolerance test (OGTT): fasting plasma glucose (FPG) ≥ 5.1 mmol/L, 1-h glucose ≥ 10.0 mmol/L, 2-h ≥ 8.5 mmol/L) [24]. GDM is often diagnosed between weeks 24 and 28 but can occur at any point during pregnancy [4]. Obstetricians, dietitians, and diabetes educators provide initial (group or individual) education for women with GDM. Then, diabetes educators and endocrinologists reviewed women’s blood glucose records every one to two weeks. The goals of blood glucose management were the targets (FPG < 5.3 mmol/L and 2-h postprandial glucose < 6.7 mmol/L) [24]. Insulin therapy is required when dietary and exercise control glucose instability is measured at a given time of day for seven days, and the glucose level is three or more times above the target value. Metformin was not prescribed.
Height was measured during the first antenatal care. Women were asked to recall their pre-pregnancy weight. On admission, weight at delivery was measured. BMI is equal to weight/height2 (kg/m2). According to the Chinese adult BMI definition standard, a BMI of 24–27.9 kg/m2 is considered excess weight, and a BMI of ≥28 kg/m2 is considered obesity [25]. Total GWG is the weight at delivery minus the pre-pregnancy weight. The pre-pregnancy BMI of Chinese women and the IOM-recommended ranges were used to develop guidelines for total GWG. The IOM guidelines recommend a total gestational weight gain of 7.0–11.5 kg for women with excess weight and 5.0–9.0 kg for women with obesity [15]. Based on birthweight, neonates were classified as large for gestational age (LGA) (90th percentile) or small for gestational age (SGA) (10th percentile) using the birthweight curve of Chinese neonates for gestational age [26]. The neonatal hypoglycemia (NH) standard was 2.6 mmol/L [27]. Macrosomia was defined as a birthweight greater than or equal to 4000 g.

2.4. Statistical Analysis

Women with GDM and excess weight/obesity were divided into three groups based on total GWG and IOM recommendations: below, within, and above the IOM. Frequency (percentage) for categorical data and mean ± standard deviation (SD) or median (IQR) for continuous data were used to create descriptive information. The independent sample student t-test was used for constant data consistent with normal distribution, while the Mann-Whitney U-test was used for inconsistent with normal distribution. And the Chi-squared test was used for categorical data. Without any addressing, all variables have less than 10% missing data. The findings of all statistical tests were statistically significant at p < 0.05. The low prevalence of SGA and LBW were 4.11% (80/1945) and 1.03% (20/1945), respectively, which were not included in further analysis.
The relationship between total GWG (reference, within) and neonatal birthweight was evaluated using multivariate logistic regression. This study used regression analysis to examine the potential impacts and variations of various BMIs on the outcomes of LGA and macrosomia in pregnant women with GDM and excess weight/obesity. Results were expressed as odds ratio (OR) and 95% confidence interval (CI), with p < 0.05 considered statistically significant. This study identified potential confounders based on univariate analysis, directed acyclic graphs (DAG), and research background, including maternal age (years), gestational age (weeks), gravidity (times), parity (times), family history of diabetes mellitus (yes/no), 75-g OGTT FPG (mmol/L), 1-h glucose (mmol/L), 2-h glucose (mmol/L), cesarean section (yes/no), macrosomia (yes/no), and neonatal gender (male/female) [3,28]. Model 1 has no covariate adjustment; Model 2 was adjusted for the confounding factors identified.
Logistic regression outcomes did not show a linear trend between the total GWG of women with GDM and excess weight/obesity and the risk of LGA and macrosomia outcomes. At the same time, Hedderson et al. suggest that women with GDM and excess weight/obesity are at higher risk for unfavorable neonatal outcomes, and their total GWG should probably not exceed the lowest value of the IOM suggested range [14]. The restricted cubic spline model can show the effect of small continuous changes in weight gain on the odds ratio value of the LGA/macrosomia outcome in the form of a continuous curve [29]. Therefore, we used a generalized linear model incorporated with a restricted cubic spline curve (RCS), the relationship between total GWG and risk of LGA and macrosomia was evaluated [30]. The nonlinear relation is considered in the nonlinear test with p < 0.05, and the nonlinear problem is analyzed using the RCS. Then a four-piecewise generalized linear model is established to calculate the inflection point. Knots were defined based on the 10th, 50th, and 90th percentiles of the total GWG distribution. Three knots of total GWG were used in the smooth curves, with excess weight (5, 11, 17) and obesity (4, 10, 18). The reference point was 7 kg for women with excess weight and 5 kg for women with obesity. The same covariates were included in this analysis, whereas all statistical analyses were completed using Stata (v.17.0; College Station, TX, USA).

2.5. Ethical Consideration

This study was approved (Approval No. 2020-022) by the Ethical Committee of Chongqing Health Center for Women and Children, which waived the need for informed consent.

3. Results

3.1. Participant Characteristics

A total of 1945 eligible participants were included in the study. Women were included with GDM and pre-pregnancy excess weight (n = 1597) or obesity (n = 348) (Figure 1). The average age of all women with GDM was 31.99 ± 4.47 years, and 27.61% were advanced maternal age (≥35 years). 52.39% of the pregnant had primiparas. 42.96% (686/1597) of women with excess weight and 58.62% (204/348) of women with obesity exceeded IOM recommendations. Maternal demographic statistics and obstetric characteristics are shown in Table 1, including their age, pre-pregnancy BMI, gestational weeks, gravidae, parity, and mode of delivery.

3.2. The Impact of Total GWG on Neonatal Birthweight

In women with excess weight/obesity and GDM, the incidences of LGA and macrosomia were 15.22%/20.69% and 8.70%/10.92%. The findings of univariate analysis of women with GDM, excess weight, and obesity are presented in Table 2 and Table 3, respectively. Since the frequency of SGA was low, and the univariate analysis was not statistically significant, additional inquiry was not carried out. Table 4 demonstrates the findings of a regression analysis of the effect of total GWG on the risk of LGA and macrosomia in women with excess weight and obesity, as well as GDM.
Total GWG in women with excess weight and below the IOM recommended-range is a protective factor for both LGA [adjusted odds ratio (aOR) 0.47, 0.29–0.76] and macrosomia (aOR 0.44, 0.23–0.84). Furthermore, excessive weight gain was a risk factor for LGA (aOR 0.1.47, 1.08–2.01) and macrosomia (aOR 1.55, 1.04–2.31) in the excess weight above group. No significant association was observed between low weight gain and the risk of LGA and macrosomia in women with obesity and those below IOM guidelines. However, excessive weight gain increased the risk of LGA (aOR 2.92, 1.33–6.41) and macrosomia (aOR 2.83, 1.03–7.72) in the group with obesity and total GWG above IOM guidelines.

3.3. Dose-Response Relationship between Total GWG and Risk of Neonatal Birthweight

Total GWG and risk of LGA. The study demonstrated that an increase in total GWG was associated with an increased risk of LGA in overweight and obese women (Figure 2a,c). Additionally, women who were overweight and had GDM exhibited a risk of LGA that was 1.63 (1.22–2.11) higher when their total GWG was 11.5 kg (Figure 2a). And, when the total GWG of women with excess weight was less than 7 kg, the lower the weight gain, the greater the protective effect on LGA. We found an overall J-shaped curve for total GWG, and the LGA in pregnant women with obesity, but only between 15.0 (aOR 1.95, 1.01–3.76) and 21.0 kg (aOR 2,37, 1.00–5.61) was statistically significant (Figure 2c).
Total GWG and risk of macrosomia. The findings demonstrated that the risk of macrosomia was positively correlated with the total GWG among pregnant women with GDM and excess weight. However, no discernible impacts were discovered for weight increases of less than 7 kg (Figure 2b). In women with obesity, the total GWG and macrosomia were inverted J-shaped curves. Weight gain of less than 5 kg is protective against macrosomia. On the contrary, the risk of macrosomia increased continuously with a weight gain of 5–13 kg, and the aOR value was between 4.38 and 5.12 after a weight gain of 13 kg (Figure 2d).

4. Discussion

This retrospective study of hospital clinical data found that the association with neonatal birthweight was estimated based on BMI characteristics of pregnant women with GDM and excess weight/obesity in China and weight gain recommendations given by IOM guidelines. The findings of this study showed that total GWG below IOM recommendations lowered the risk of LGA and macrosomia and remained steady following the correction model, regardless of pre-pregnancy excess weight or obesity. The neonatal birthweight (LGA/macrosomia) was higher in pregnant women with GDM and obesity who exceeded IOM guidelines. The total GWG range in women with GDM and excess weight or obesity has been studied recently, although no adequate guidelines are still available [31].
Ke et al. reported that excessive weight gain in excess weight/obese women is associated with a higher risk of LGA and macrosomia [32]. In a study by Ping et al., a retrospective cohort analysis of GWG for GDM showed that women with GWG above IOM guidelines had a significant risk of cesarean section, macrosomia, and LGA [33]. In addition, meta-analysis by Vats et al. showed that preconception excess weight/obesity was also significantly associated with the risk of macrosomia and LGA [34]. However, our findings contradict current racial and national reports of women with GDM exceeding the IOM guideline range for LGA and macrosomia at high risk, particularly in women who are overweight or obese before pregnancy [35]. The combined effects of abnormal glucose metabolism in women with GWG and GDM on poor birthweight outcomes require more specific and appropriate GWG recommendations based on their metabolic status.
Furthermore, in pre-pregnancy excess weight/obese women, combining GDM and total GWG may increase maternal circulation-free fatty acid and triglyceride levels via pathophysiological pathways [36]. At the same time, excessive weight gain and fat accumulation induce GDM-sensitive biological responses, including insulin resistance, lipotoxicity, and dyslipidemia [37]. These pathophysiological elements may cause the hyperglycemic maternal uterus to accelerate fetal growth excessively. The results highlight the significance of a healthy weight gain for fetal growth and development in pre-pregnancy obese or overweight women with GDM.
In line with what was previously stated by Catov et al., GDM women in this study who were overweight or obese before becoming pregnant were more likely to have a total GWG higher than the IOM-recommended range [38]. The restricted cubic spline model can use a continuous curve to show the effect of changes in weight gain on the LGA/macrosomia outcome odds ratio value. Thus, we further analysis of the dose-response relationship between total GWG and LGA in excess weight/obese and GDM women showed that the risk of LGA and macrosomia arises when the total weight gain in excess weight/obese and GDM women exceeds the lower limit (7 kg/5 kg) of the IOM-recommended range, respectively. The risk of LGA and macrosomia increased along with weight gain. Our findings support a systematic review by Goldstein et al. that found a continuous rather than a threshold connection between excess GWG and newborn weight outcomes [11].
As a result, there was a linear trend in the dose-response data for pre-pregnancy excess weight/obesity, total weight growth of GDM, and neonatal weight, and it may be easier to understand the effects of varied weight gain on LGA and macrosomia. Nevertheless, our findings suggest that the range recommended by the IOM may not apply to women with GDM and pre-pregnant excess weight/obesity. Xu et al. studied using modified GWG targets (2 kg less from the upper and lower limits of the IOM recommended range) for lower LGA and macrosomia incidence than the original IOM targets [39].
Furthermore, women with obesity and GDM who have total GWG below IOM guidelines had a reduced risk of macrosomia, which means that the neonatal weight was more indicative of fetal growth [40]. The dose-response results of total weight gain and neonatal weight showed a linear trend, which could more intuitively see the risk of different weight gain on LGA and macrosomia. The outcomes of this study indicate the significance of weight management for pregnant women with GDM who are overweight or obese to reduce weight gain and maintain a healthy weight during pregnancy. Ferreira et al. studied total weight gain below IOM recommendations showing benefits in improving adverse pregnancy outcomes [41]. Therefore, in clinical practice, GDM and weight gain in overweight/obese women should be strictly controlled, and uniform standards for total GWG reduction (below the IOM recommendations) should be formulated to ensure adequate fetal growth.
In contrast, there was no statistically significant difference between weight gains based on IOM and SGA in our study among women who were overweight or obese. In addition, no adverse effects of decreased weight gain on low birthweight outcomes were discovered in research participants who were overweight or obese and had GDM, demonstrating the safety of reducing weight gain [42]. More recently, Huang et al. also showed that women with GDM who had GWG below the guidelines did not increase the risk of SGA, although SGA babies had more adverse outcomes in newborns born to mothers with GDM [43]. Additionally, Drever et al.’s analysis of a clinical picture with decreased preconception BMI, fasting blood glucose levels, and baseline USS growth measurements alone may indicate that women with GDM only need minimal active glucose management to prevent SGA [44]. Furthermore, Monteiro et al. found that only women with normal and low pre-pregnancy BMI and a GWG below 3 kg had a higher risk of SGA [45].
In addition, further proof from pertinent studies is needed to compensate for sample size, population characteristics, and other aspects. In particular, the total GWG data distribution for women with GDM and excess weight/obesity included was small on both sides of the tail sample size in this study. Although, the truncated power basis of the RCS allows linear extrapolation outside of the external nodes. However, extrapolation can still be dangerous when the external nodes are on the tails of both sides of the data. Therefore, the results of this study can provide a basis for the formulation of a reasonable total GWG among women with GDM and excess weight/obesity. But further large-scale, multi-center prospective studies are needed to external validate and recalibrate the appropriate GWG externally.
Besides, total GWG has been associated with a higher risk of poor newborn outcomes in women with pre-pregnancy obesity and GDM [31,46]. However, differences in endocrine metabolism caused by pre-pregnancy excess weight/obesity and heterogeneity in the diagnosis and treatment of GDM may impact all gestational weight gain. At the same time, blood glucose control and pregnancy weight gain are mutually complementary, and the study of Lai et al. showed that more rational weight control is also conducive to the ideal blood glucose control effect (HbA1c < 6%) [47]. Controlling weight gain during pregnancy should be a priority after diagnosis of GDM to optimize pregnancy outcomes and improve postpartum glucose homeostasis, especially in women with excess weight/obese [48]. It is necessary to conduct additional research to investigate phased and revised criteria for weight growth during pregnancy and identify the influence of weight gain during pregnancy on neonatal outcomes in women who have GDM and who are overweight or obese.
This study offers several potential benefits. IOM-recommended criteria were used in the first step of this study, which consisted of performing disaggregated analyses to identify the impact of excess weight/obesity in mothers on the outcomes of newborn birthweight. However, the dose-response relationship between total GWG and adverse neonatal birthweight outcomes was assessed by RCS in this study, which provides a visual understanding of total GWG and the risk of adverse outcomes. Second, this study provides a reference for the formulation of weight gain guidelines according to the characteristics of BMI in Chinese women.
The present study has some limitations. First, the sample size of this study may not be large enough to draw definitive conclusions, and extensive cohort studies of excess weight/obesity who had GDM are needed to support the development of appropriate weight gain guidelines. Second, the sample consisted of Chinese women with excess weight/obese and had gestational diabetes, and ethnic characteristics should be considered and may limit the generalizability of the study findings in other populations. Third, all the information and data used in this investigation came from computerized medical records, and varying measures may yield different results. Fourth, the pre-pregnancy weight of GDM women was estimated using recall and self-reporting, which could introduce bias. Last, this study only analyzed the relationship between total GWG and adverse neonatal birthweight outcomes, and these results need to be viewed critically. The various methods of recording and analyzing GWG data, such as weight gain before the diagnosis of GDM and subsequent weight gain over different gestational periods, can contribute new information to the study’s findings.

5. Conclusions

This study found that LGA and macrosomia are dose-responsive to increased gestational weight gain in women who have excess weight or have GDM, and the risk of weight gain exceeding the lower limit of the IOM recommended range was already present. These results suggest that GWG in women with GDM falls short of the IOM-recommended range for beneficial birthweight. Not only is glucose management essential to lowering the risk of macrosomia and LGA, but there is an urgent need for studies to establish suitable weight gain methods for women who are overweight or obese and have GDM. According to the findings, weight management programs should specifically target women with pre-pregnancy excess weight/obesity and GDM to prevent excessive total GWG. Large-scale population studies should be required to evaluate the effects of total GWG reduction in perinatal and postpartum long-term maternal and neonatal outcomes, especially for neonatal birthweight. Meanwhile, it is critical to prevent excess weight and obesity in women of reproductive age to lower the prevalence of GDM associated with obesity and persistent excess weight during pregnancy, improving both maternal and newborn health.

Author Contributions

Conceptualization, J.H., K.H., B.W., Z.C. and H.W.; methodology, J.H., K.H. and B.W.; software, J.H.; formal analysis, J.H.; investigation, J.H., K.H. and Z.C.; resources, J.H. and Z.C.; data curation, J.H. and H.W.; writing—original draft preparation, J.H.; writing—review and editing, J.H. and H.W.; visualization, J.H.; supervision, H.W.; project administration, Z.C. and H.W.; funding acquisition, H.W. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Research financed by the Research Major Project for Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology (Number 2022C06) and Wuhan Nursing Association in China (Number WHHL2s2201).

Institutional Review Board Statement

This study was approved by the Ethical Committee of Chongqing Health Center for Women and Children, which waived the need for informed consent (NO. 2020-022).

Informed Consent Statement

This was a retrospective study; consent was not needed.

Data Availability Statement

The data presented in this study are available on request from the corresponding author. The data are not publicly available due to ethical, legal, or privacy issues are present.

Acknowledgments

The authors thank obstetricians (Yu Yan and Jianxin Li) at Chongqing Health Center for Women and Children at the time of data collection for their assistance in data collection.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Najafi, F.; Hasani, J.; Izadi, N.; Hashemi-Nazari, S.-S.; Namvar, Z.; Mohammadi, S.; Sadeghi, M. The effect of prepregnancy body mass index on the risk of gestational diabetes mellitus: A systematic review and dose-response meta-analysis. Obes. Rev. 2019, 20, 472–486. [Google Scholar] [CrossRef]
  2. Bogdanet, D.; Egan, A.; Reddin, C.; Kirwan, B.; Carmody, L.; Dunne, F. ATLANTIC DIP: Despite insulin therapy in women with IADPSG diagnosed GDM, desired pregnancy outcomes are still not achieved. What are we missing? Diabetes Res. Clin. Pract. 2018, 136, 116–123. [Google Scholar] [CrossRef]
  3. McIntyre, H.D.; Catalano, P.; Zhang, C.; Desoye, G.; Mathiesen, E.R.; Damm, P. Gestational diabetes mellitus. Nat. Rev. Dis. Primers 2019, 5, 48. [Google Scholar] [CrossRef]
  4. ElSayed, N.A.; Aleppo, G.; Aroda, V.R.; Bannuru, R.R.; Brown, F.M.; Bruemmer, D.; Collins, B.S.; Hilliard, M.E.; Isaacs, D.; Johnson, E.L.; et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care 2023, 46, S19–S40. [Google Scholar] [CrossRef]
  5. Landon, M.B.; Spong, C.Y.; Thom, E.; Carpenter, M.W.; Ramin, S.M.; Casey, B.; Wapner, R.J.; Varner, M.W.; Rouse, D.J.; Thorp, J.M., Jr.; et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N. Engl. J. Med. 2009, 361, 1339–1348. [Google Scholar] [CrossRef]
  6. Crowther, C.A.; Samuel, D.; McCowan, L.M.E.; Edlin, R.; Tran, T.; McKinlay, C.J. Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes. N. Engl. J. Med. 2022, 387, 587–598. [Google Scholar] [CrossRef]
  7. He, J.; Chen, X.; Wang, Y.; Liu, Y.; Bai, J. The experiences of pregnant women with gestational diabetes mellitus: A systematic review of qualitative evidence. Rev. Endocr. Metab. Disord. 2021, 22, 777–787. [Google Scholar] [CrossRef]
  8. Benhalima, K.; Robyns, K.; Van Crombrugge, P.; Deprez, N.; Seynhave, B.; Devlieger, R.; Verhaeghe, J.; Mathieu, C.; Nobels, F. Differences in pregnancy outcomes and characteristics between insulin- and diet-treated women with gestational diabetes. BMC Pregnancy Childbirth 2015, 15, 271. [Google Scholar] [CrossRef]
  9. Barnes, R.A.; Wong, T.; Ross, G.P.; Griffiths, M.M.; Smart, C.E.; Collins, C.E.; MacDonald-Wicks, L.; Flack, J.R. Excessive Weight Gain Before and During Gestational Diabetes Mellitus Management: What Is the Impact? Diabetes Care 2020, 43, 74–81. [Google Scholar] [CrossRef]
  10. Poppe, K. Management of endocrine diseases: Thyroid and female infertility: More questions than answers?! Eur. J. Endocrinol. 2021, 184, R123–R135. [Google Scholar] [CrossRef]
  11. Goldstein, R.F.; Abell, S.K.; Ranasinha, S.; Misso, M.; Boyle, J.A.; Black, M.H.; Li, N.; Hu, G.; Corrado, F.; Rode, L.; et al. Association of Gestational Weight Gain with Maternal and Infant Outcomes: A Systematic Review and Meta-analysis. JAMA 2017, 317, 2207–2225. [Google Scholar] [CrossRef] [PubMed]
  12. Ionescu, R.F.; Enache, R.M.; Cretoiu, S.M.; Gaspar, B.S. Gut Microbiome Changes in Gestational Diabetes. Int. J. Mol. Sci. 2022, 23, 12839. [Google Scholar] [CrossRef] [PubMed]
  13. Komem, D.; Salman, L.; Krispin, E.; Arbib, N.; Bardin, R.; Wiznitzer, A.; Hadar, E. Gestational weight gain and weight loss among women with gestational diabetes mellitus. Diabetes Res. Clin. Pract. 2018, 141, 88–97. [Google Scholar] [CrossRef]
  14. Hedderson, M.M.; Brown, S.D.; Ehrlich, S.F.; Tsai, A.L.; Zhu, Y.; Quesenberry, C.P.; Crites, Y.; Ferrara, A. A Tailored Letter Based on Electronic Health Record Data Improves Gestational Weight Gain Among Women With Gestational Diabetes Mellitus: The Gestational Diabetes’ Effects on Moms (GEM) Cluster-Randomized Controlled Trial. Diabetes Care 2018, 41, 1370–1377. [Google Scholar] [CrossRef] [PubMed]
  15. Institute of Medicine; National Research Council Committee to Reexamine. Pregnancy Weight Guidelines: The National Academies Collection: Reports funded by National Institutes of Health; National Academies Press: Washington, DC, USA, 2009. [Google Scholar]
  16. Wong, T.; Barnes, R.A.; Ross, G.P.; Cheung, N.W.; Flack, J.R. Are the Institute of Medicine weight gain targets applicable in women with gestational diabetes mellitus? Diabetologia 2017, 60, 416–423. [Google Scholar] [CrossRef]
  17. Harper, L.M.; Tita, A.; Biggio, J.R. The institute of medicine guidelines for gestational weight gain after a diagnosis of gestational diabetes and pregnancy outcomes. Am. J. Perinatol. 2015, 32, 239–246. [Google Scholar]
  18. Minschart, C.; Lammertyn, A.; Van Crombrugge, P.; Moyson, C.; Verhaeghe, J.; Vandeginste, S.; Verlaenen, H.; Vercammen, C.; Maes, T.; Dufraimont, E.; et al. Low Gestational Weight Gain in Women with Gestational Diabetes Is Safe with Better Metabolic Profile Postpartum. J. Clin. Endocrinol. Metab. 2023, 108, 665–679. [Google Scholar] [CrossRef]
  19. He, J.; Hu, K.; Xing, C.; Wang, B.; Zeng, T.; Wang, H. Puerperium experience and lifestyle in women with gestational diabetes mellitus and overweight/obesity in China: A qualitative study. Front. Psychol. 2023, 14, 1043319. [Google Scholar] [CrossRef]
  20. Mustaniemi, S.; Nikkinen, H.; Bloigu, A.; Pouta, A.; Kaaja, R.; Eriksson, J.G.; Laivuori, H.; Gissler, M.; Kajantie, E.; Vaarasmaki, M. Normal Gestational Weight Gain Protects from Large-for-Gestational-Age Birth among Women with Obesity and Gestational Diabetes. Front. Public Health 2021, 9, 550860. [Google Scholar] [CrossRef]
  21. Luo, X.; Gao, J.; He, Z.; Ji, J.; Zhang, W.; Wu, P.; Guo, X.; Cao, D.; Xu, Z.; Li, C.; et al. What is an appropriate gestational weight gain for women with gestational diabetes mellitus: Based on the adverse pregnancy outcomes of over 12 thousand participants? Diabetol. Metab. Syndr. 2022, 14, 166. [Google Scholar] [CrossRef]
  22. Shi, X.; Wang, D.; Lin, M.; Su, W.; Wang, L.; Xiao, F.; Huang, P.; Liu, W.; Zeng, J.; Song, H.; et al. Maternal gestational diabetes mellitus and offspring body mass index frm 1 to 4 years. Endocr. Pract. 2020, 26, 619–626. [Google Scholar] [CrossRef] [PubMed]
  23. von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gøtzsche, P.C.; Vandenbroucke, J.P. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. Int. J. Surg. 2014, 12, 1495–1499. [Google Scholar] [CrossRef]
  24. Group of Obstetrics Chinese Society of Obstetrics and Gynecology; Gestational Diabetes Mellitus Collaborative Group Chinese Perinatal Medicine Society. Guidelines for Diagnosis and treatment of gestational Diabetes Mellitus (2014). Chin. J. Obstetr. Gynecol. 2014, 49, 561–569. [Google Scholar]
  25. Working Group on Obesity in China. Guidelines for Prevention and Control of Overweight and Obesity in Chinese Adults (Excerpt). Acta Nutr. Sin. 2004, 17, 1–4. [Google Scholar]
  26. Zhu, L.; Zhang, R.; Zhang, S.; Shi, W.; Yan, W.; Wang, X.; Lyu, Q.; Liu, L.; Zhou, Q.; Qiu, Q. Chinese neonatal birth weight curve for different gestational age. Chin. J. Pediatr. 2015, 53, 97–103. [Google Scholar]
  27. Wackernagel, D.; Gustafsson, A.; Edstedt Bonamy, A.K.; Reims, A.; Ahlsson, F.; Elfving, M.; Domellöf, M.; Hansen Pupp, I. Swedish national guideline for prevention and treatment of neonatal hypoglycaemia in newborn infants with gestational age ≥35 weeks. Acta Paediatr. 2020, 109, 31–44. [Google Scholar] [CrossRef] [PubMed]
  28. Textor, J.; Hardt, J.; Knüppel, S. DAGitty: A Graphical Tool for Analyzing Causal Diagrams. Epidemiology 2011, 22, 745. [Google Scholar] [CrossRef] [PubMed]
  29. Luo, J.; Jin, H.; Li, B. The Application of Restricted Cubic Spline in Nonlinear Re-gression. Chin. J. Health Stat. 2010, 27, 229–232. [Google Scholar]
  30. Zhang, X.; Yu, D.; Zou, G.; Liang, H. Optimal Model Averaging Estimation for Generalized Linear Models and Generalized Linear Mixed-Effects Models. J. Am. Stat. Assoc. 2016, 111, 1775–1790. [Google Scholar] [CrossRef]
  31. Wu, S.; Jin, J.; Hu, K.-L.; Wu, Y.; Zhang, D. Prevention of Gestational Diabetes Mellitus and Gestational Weight Gain Restriction in Overweight/Obese Pregnant Women: A Systematic Review and Network Meta-Analysis. Nutrients 2022, 14, 2383. [Google Scholar] [CrossRef]
  32. Ke, J.-F.; Liu, S.; Ge, R.-L.; Ma, L.; Li, M.-F. Associations of maternal pre-pregnancy BMI and gestational weight gain with the risks of adverse pregnancy outcomes in Chinese women with gestational diabetes mellitus. BMC Pregnancy Childbirth 2023, 23, 414. [Google Scholar] [CrossRef] [PubMed]
  33. Shi, P.; Liu, A.; Yin, X. Association between gestational weight gain in women with gestational diabetes mellitus and adverse pregnancy outcomes: A retrospective cohort study. BMC Pregnancy Childbirth 2021, 21, 508. [Google Scholar] [CrossRef] [PubMed]
  34. Vats, H.; Saxena, R.; Sachdeva, M.P.; Walia, G.K.; Gupta, V. Impact of maternal pre-pregnancy body mass index on maternal, fetal and neonatal adverse outcomes in the worldwide populations: A systematic review and meta-analysis. Obes. Res. Clin. Pract. 2021, 15, 536–545. [Google Scholar] [CrossRef] [PubMed]
  35. Sun, Y.; Shen, Z.; Zhan, Y.; Wang, Y.; Ma, S.; Zhang, S.; Liu, J.; Wu, S.; Feng, Y.; Chen, Y.; et al. Effects of pre-pregnancy body mass index and gestational weight gain on maternal and infant complications. BMC Pregnancy Childbirth 2020, 20, 390. [Google Scholar] [CrossRef]
  36. Kurtzhals, L.L.; Nørgaard, S.K.; Secher, A.L.; Nichum, V.L.; Ronneby, H.; Tabor, A.; McIntyre, H.D.; Damm, P.; Mathiesen, E.R. The impact of restricted gestational weight gain by dietary intervention on fetal growth in women with gestational diabetes mellitus. Diabetologia 2018, 61, 2528–2538. [Google Scholar] [CrossRef]
  37. Ahmed, B.; Sultana, R.; Greene, M.W. Adipose tissue and insulin resistance in obese. Biomed. Pharmacother. 2021, 137, 111315. [Google Scholar] [CrossRef]
  38. Catov, J.M.; Sun, B.; Lewis, C.E.; Bertolet, M.; Gunderson, E.P. Prepregnancy weight change associated with high gestational weight gain. Obesity 2022, 30, 524–534. [Google Scholar] [CrossRef]
  39. Xu, Q.; Ge, Z.; Hu, J.; Shen, S.; Bi, Y.; Zhu, D. The association of gestational weight gain and adverse pregnancy outcomes in women with gestational diabetes mellitus. Endocr. Pract. 2019, 25, 1137–1150. [Google Scholar] [CrossRef]
  40. Hong, M.; Liang, F.; Zheng, Z.; Chen, H.; Guo, Y.; Li, K.; Liu, X. Weight gain rate in the second and third trimesters and fetal growth in women with gestational diabetes mellitus: A retrospective cohort study. BMC Pregnancy Childbirth 2022, 22, 424. [Google Scholar] [CrossRef]
  41. Lima Ferreira, J.; Voss, G.; Dória, M.; Couto, A.S.; Príncipe, R.M. Benefit of insufficient gestational weight gain in obese women with gestational diabetes mellitus: A multicenter study in Portugal. Diabetes Metab. Syndr. 2021, 15, 419–424. [Google Scholar] [CrossRef]
  42. Yuanmei, L.; Qian, Z.; Fengsen, X.; Yankui, W. Restricted gestational weight gain in overweight/obese women with gestational diabetes mellitus and pregnancy outcomes. CEOG 2019, 46, 763–769. [Google Scholar] [CrossRef]
  43. Huang, D.; Liang, M.; Xu, B.; Chen, S.; Xiao, Y.; Liu, H.; Yin, D.; Yang, J.; Wang, L.; Pan, P.; et al. The association of insufficient gestational weight gain in women with gestational diabetes mellitus with adverse infant outcomes: A case-control study. Front. Public Health 2023, 11, 1054626. [Google Scholar] [CrossRef] [PubMed]
  44. Drever, H.J.J.; Davidson, S.J.J.; Callaway, L.K.K.; Sekar, R.; de Jersey, S.J.J. Factors associated with higher risk of small-for-gestational-age infants in women treated for gestational diabetes. Aust. N. Z. J. Obstet. Gynaecol. 2023. [Google Scholar] [CrossRef] [PubMed]
  45. Monteiro, S.S.; Santos, T.S.; Fonseca, L.; Saraiva, M.; Pichel, F.; Pinto, C.; Pereira, M.T.T.; Vilaverde, J.; Almeida, M.C.C.; Dores, J. Inappropriate gestational weight gain impact on maternofetal outcomes in gestational diabetes. Ann. Med. 2023, 55, 207–214. [Google Scholar] [CrossRef]
  46. Miao, M.; Dai, M.; Zhang, Y.; Sun, F.; Guo, X.; Sun, G. Influence of maternal overweight, obesity and gestational weight gain on the perinatal outcomes in women with gestational diabetes mellitus. Sci. Rep. 2017, 7, 305. [Google Scholar] [CrossRef]
  47. Lai, M.; Weng, J.; Yang, J.; Gong, Y.; Fang, F.; Li, N.; Kang, M.; Xu, X.; Wang, Y. Effect of continuous glucose monitoring compared with self-monitoring of blood glucose in gestational diabetes patients with HbA1c < 6%: A randomized controlled trial. Front. Endocrinol. 2023, 14, 1174239. [Google Scholar]
  48. Aiken, C.E.M.; Hone, L.; Murphy, H.R.; Meek, C.L. Improving outcomes in gestational diabetes: Does gestational weight gain matter? Diabet. Med. 2019, 36, 167–176. [Google Scholar] [CrossRef]
Healthcare 11 02358 g001
Figure 1. Flow chart for the study population. BMI, body mass index (kg/m2); GDM, gestational diabetes mellitus.
Figure 1. Flow chart for the study population. BMI, body mass index (kg/m2); GDM, gestational diabetes mellitus.
Healthcare 11 02358 g001
Healthcare 11 02358 g002
Figure 2. Dose-response relationship between total GWG and risk of LGA and macrosomia. LGA, large for gestational age; GDM, gestational diabetes mellitus; GWG, gestational weight gain; the solid line represents OR; the dotted lines represent the 95% confidence interval (CI); (a,b) for pregnant women with GDM and excess weight; (c,d) for pregnant women with GDM and obesity.
Figure 2. Dose-response relationship between total GWG and risk of LGA and macrosomia. LGA, large for gestational age; GDM, gestational diabetes mellitus; GWG, gestational weight gain; the solid line represents OR; the dotted lines represent the 95% confidence interval (CI); (a,b) for pregnant women with GDM and excess weight; (c,d) for pregnant women with GDM and obesity.
Healthcare 11 02358 g002
Table 1. Characteristics of participants and obstetric information (n = 1945).
Table 1. Characteristics of participants and obstetric information (n = 1945).
CharacteristicClassificationNo. (%)
Age, years18–2463 (3.24)
25–29516 (26.53)
30–34829 (42.62)
35–39427 (21.95)
40–4498 (5.04)
≥4512 (0.62)
Pregestational BMI, kg/m224.0–27.91597 (82.11)
≥28.0348 (17.89)
Gestational age at delivery,
weeks + days		37–37+6207 (10.64)
38–38+6679 (34.91)
39–39+6696 (35.78)
40–40+6351 (18.05)
41–41+612 (0.62)
Gravidae1546 (28.07)
2515 (26.48)
3397 (20.41)
4250 (12.85)
≥5236 (12.13)
Unknown1 (0.05)
Parity01019 (52.39)
1845 (43.44)
275 (3.86)
34 (0.21)
≥41 (0.05)
Unknown1 (0.05)
Delivery modeSpontaneous delivery703 (36.14)
Cesarean section1242 (63.86)
Table 2. Univariate analysis of women with GDM and excess weight (n = 1597).
Table 2. Univariate analysis of women with GDM and excess weight (n = 1597).
VariablesBelow (n = 331)Within (n = 580)Above (n = 686)p
Age, year32.33 ± 4.5732.24 ± 4.3731.69 ± 4.490.051
Gestational age, weeks38.61 ± 0.9138.70 ± 0.9238.62 ± 0.920.262
Gravida, times2.72 ± 1.562.61 ± 1.622.58 ± 1.540.294
Parity, times0.56 ± 0.590.53 ± 0.600.49 ± 0.580.151
Family history of T2DM54 (16.31)82 (14.14)85 (12.39)0.229
OGTT fasting, mmol/L5.05 ± 0.675.01 ± 0.815.00 ± 0.650.298
OGTT 1-h, mmol/L10.63 ± 1.7510.37 ± 1.6810.15 ± 1.80<0.001 *
OGTT 2-h, mmol/L9.01 ± 1.678.64 ± 1.738.50 ± 1.79<0.001 *
Insulin40 (12.08)70 (12.07)69 (10.06)0.450
Preeclampsia11 (3.32)28 (4.83)38 (5.54)0.303
Caesarean section197 (59.52)335 (54.76)474 (69.10)<0.001 *
Neonatal gender, male178 (53.78)294 (50.69)373 (54.37)0.399
Macrosomia12 (3.63)46 (7.93)81 (11.81)<0.001 *
NH16 (4.83)34 (5.86)56 (8.16)0.087
LGA24/348 (6.90)83/602 (13.79)136/710 (19.15)<0.001 *
SGA17/348 (4.89)22/602 (3.65)24/710 (3.38)0.477
NHB9 (2.72)20 (3.45)36 (5.25)0.102
* p < 0.05, Values, mean ± standard deviation by student t-test and number (%) by Chi-squared test; T2DM, type 2 diabetes mellitus; OGTT, oral glucose tolerance test; NH, neonatal hypoglycemia; LGA, large for gestational age; LBW, low birth weight; SGA, small for gestational age; NHB, neonatal hyperbilirubinemia.
Table 3. Univariate analysis of women with GDM and obesity (n = 348).
Table 3. Univariate analysis of women with GDM and obesity (n = 348).
VariablesBelow (n = 56)Within (n = 88)Above (n = 204)p
Age, year31.48 ± 4.2032.34 ± 4.6731.72 ± 4.510.400
Gestational age, weeks38.44 ± 1.0038.52 ± 0.9338.62 ± 0.910.705
Gravida, times2.82 ± 1.622.55 ± 1.582.75 ± 1.530.446
Parity, times0.51 ± 0.570.52 ± 0.550.55 ± 0.620.926
Family history of T2DM6 (10.71)15 (17.05)34 (16.67)0.520
OGTT fasting, mmol/L5.16 ± 0.585.24 ± 0.755.11 ± 0.580.450
OGTT 1-h, mmol/L10.45 ± 1.6110.50 ± 1.9310.51 ± 1.600.830
OGTT 2-h, mmol/L8.52 ± 1.738.72 ± 1.888.57 ± 1.550.813
Insulin11 (19.64)13 (14.77)31 (15.20)0.688
Preeclampsia3 (5.36)8 (9.09)28 (13.73)0.163
Caesarean section32 (57.14)61 (69.32)143 (70.10)0.174
Neonatal gender, male24 (42.86)42 (47.73)96 (47.06)0.828
Macrosomia2 (3.57)7 (7.95)29 (14.22)0.045 *
NH4 (7.14)10 (11.36)17 (8.33)0.621
LGA9/61 (14.75)11/92 (11.96)52/212 (24.53)0.022 *
SGA5/61 (8.20)4/92 (4.35)8/212 (3.77)0.197
NHB1 (1.79)4 (4.55)12 (5.88)0.213
* p < 0.05, Values, mean ± standard deviation by student t-test and number (%) by Chi-squared test; T2DM, type 2 diabetes mellitus; OGTT, oral glucose tolerance test; NH, neonatal hypoglycemia; LGA, large for gestational age; LBW, low birth weight; SGA, small for gestational age; NHB, neonatal hyperbilirubinemia.
Table 4. Association of total GWG of women with GDM and excess weight/obesity and neonatal birthweight.
Table 4. Association of total GWG of women with GDM and excess weight/obesity and neonatal birthweight.
Neonatal BirthweightPre-BMI and Total GWGaOR (95% CI)pOR (95% CI)p
LGAExcess weight for below IOM0.465 (0.287–0.755)0.002 *0.468 (0.291–0.753)0.002 *
Excess weight for above IOM1.658 (0.812–3.517)0.3311.340 (0.517–3.475)0.547
Obesity for below IOM1.470 (1.077–2.006)0.015 *1.481 (1.098–1.996)0.010 *
Obesity for above IOM2.920 (1.331–6.406)0.008 *2.395 (1.182–4.851)0.015 *
MacrosomiaExcess weight for below IOM0.444 (0.230–0.858)0.016 *0.437 (0.228–0.837)0.013 *
Excess weight for above IOM1.707 (0.822–3.546)0.5470.429 (0.086–2.141)0.302
Obesity for below IOM1.550 (1.043–2.305)0.030 *1.554 (1.063–2.273)0.023 *
Obesity for above IOM2.825 (1.034–7.716)0.043 *1.918 (0.806–5.561)0.141
* p < 0.05, GWG, gestational weight gain; LGA, large for gestational age; OR, odds ratio, aOR, adjust odds ratio, 95% CI, confidence interval; IOM, Institute of Medicine; pre-BMI, pre-pregnancy body mass index.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

He, J.; Hu, K.; Wang, B.; Chen, Z.; Wang, H. Dose-Response Relationship between Gestational Weight Gain and Neonatal Birthweight in Chinese Women with Excess Weight/Obesity and Gestational Diabetes Mellitus. Healthcare 2023, 11, 2358. https://doi.org/10.3390/healthcare11162358

AMA Style

He J, Hu K, Wang B, Chen Z, Wang H. Dose-Response Relationship between Gestational Weight Gain and Neonatal Birthweight in Chinese Women with Excess Weight/Obesity and Gestational Diabetes Mellitus. Healthcare. 2023; 11(16):2358. https://doi.org/10.3390/healthcare11162358

Chicago/Turabian Style

He, Jing, Kaili Hu, Binghua Wang, Zhen Chen, and Hui Wang. 2023. "Dose-Response Relationship between Gestational Weight Gain and Neonatal Birthweight in Chinese Women with Excess Weight/Obesity and Gestational Diabetes Mellitus" Healthcare 11, no. 16: 2358. https://doi.org/10.3390/healthcare11162358

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop